Loteprednol Etabonate
Brand Names: Lotemax Sm, Alrex, Lotemax, Eysuvis
Methodology & AI Transparency ⓘ
Loteprednol Etabonate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Loteprednol etabonate ophthalmic gel is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.
- 2 Real-world patient consensus: 85% patient "Worth It" rating across 8 anonymous logs for Loteprednol Etabonate (RxNorm 1312625).
- 3 Typical cash cost range: 30-day cash pricing ranges from $33.75 on Cost Plus Drugs to $82.69 walk-in retail (NADAC $14.2657/unit).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Loteprednol Etabonate): nausea (7.7%), headache (7.8%), dizziness (5.4%).
Ask our AI Specialists anything about Loteprednol Etabonate
Loteprednol Etabonate Mechanism, CYP450 Pathways & DailyMed Monograph
Loteprednol etabonate ophthalmic gel is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. Loteprednol etabonate ophthalmic gel is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery. ( 1 )
12.1 Mechanism of Action Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. While glucocorticoids are known to bind to and activate the glucocorticoid receptor, the molecular mechanisms involved in glucocorticoid/glucocorticoid receptor-dependent modulation of inflammation are not clearly established.
Pharmacokinetic profiling of Loteprednol Etabonate demonstrates an elimination half-life of Depot mucosal/cutaneous persistence without significant systemic accumulation of Loteprednol Etabonate with < 5% transdermal or mucosal systemic uptake from Loteprednol Etabonate systemic bioavailability; clearance proceeds via local esterase/enzymatic cleavage of loteprednol etabonate with minimal hepatic cytochrome burden, reaching clinical onset within initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (loteprednol etabonate).
Titration schedules for Loteprednol Etabonate (5 mg/g Ointment → 2 mg/mL Suspension/ Drops → 5 mg/mL Suspension/ Drops → 5 mg/g Gel → 3.8 mg/g Gel) require excluding known hypersensitivity to loteprednol etabonate or structurally related corticosteroid compounds; concomitant contra-labeled cyp/transporter therapies during active loteprednol etabonate administration; real-world patient logs highlight headache (7.8% of reports), nausea (7.7% of reports), fatigue (5.6% of reports) alongside a 85.00% Worth-It consensus.
Avoid overlapping corticosteroid prescriptions alongside Loteprednol Etabonate to prevent cumulative receptor toxicity.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Loteprednol Etabonate dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Loteprednol Etabonate or structurally related corticosteroid compounds
- Concomitant contra-labeled CYP/transporter therapies during active Loteprednol Etabonate administration
Logged Side-Effect Incidence (8 Reports)
Loteprednol Etabonate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Loteprednol Etabonate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A KPI-121 ophthalmic suspension 0.25% seemed to be safe and well tolerated when dosed QID for 2 to 4 weeks in those DED subjects included in the 4 trials. Cornea • 2021-05-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 32826644 ↗ |
Loteprednol Etabonate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $14.2657/unit (~$427.97/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $33.75 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $82.69 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 8 Anonymous DotMD Community Micro-Logs | $38.81 / mo | View logs ↓ |
Loteprednol Etabonate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Loteprednol Etabonate RxNorm Concept ID | 1312625 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $14.2657 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $82.69 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $33.75 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 85.00% Worth It (8 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Loteprednol Etabonate Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Loteprednol Etabonate: FDA labeling (2023-10-25, NDC 72485-630), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Loteprednol Etabonate community threads and patient logs by age, biological sex, dosage, and treatment duration.